Evaluation of antibodies against mpox virus M1R.
- Author:
Yawen LIU
1
;
Sai YANG
2
;
Yi YANG
3
;
Jingshu XIE
3
;
Hua YANG
1
;
Yan LI
2
Author Information
- Publication Type:Journal Article
- Keywords: humanized mice; monkeypox M1R antigen; neutralizing antibody; protective antibody
- MeSH: Animals; Mice; Antibodies, Viral/immunology*; Monkeypox virus/immunology*; Mpox, Monkeypox/immunology*; Antibodies, Neutralizing/immunology*; Viral Envelope Proteins/immunology*; Humans; Antibodies, Monoclonal/biosynthesis*; Female
- From: Chinese Journal of Biotechnology 2025;41(8):3131-3142
- CountryChina
- Language:Chinese
- Abstract: The global outbreak of monkeypox in 2022 has aroused widespread concern in public health. To date, the prevention and treatment of monkeypox has mainly relied on smallpox vaccines and drugs. This study aims to screen and obtain therapeutic antibodies with high affinity, neutralizing activity, and protective effects, and provide candidate molecules for the development of specific therapeutic antibodies against monkeypox. Therefore, humanized mice were immunized to screen for antibodies against the envelope protein of the mpox virus. Two M1R-specific antibodies, 12G5 and 12H6, were obtained, with the affinity of 0.095 nmol/L and 0.089 nmol/L, respectively. The 50% reduction of the plaque counts (PRNT50) of 12G5 and 12H6 was (1.821±1.766) μg/mL and (17.605±2.383) μg/mL, respectively. The two antibodies targeted two binding epitopes of M1R. Moreover, 12H6 could protect 60% of mice from death following the vaccinia virus challenge. This study provides research materials for subsequent in-depth studies on the immunoprotection of mpox virus and potential therapeutic strategies.
